{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:33:59Z","timestamp":1794576839058,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20005"],"award-info":[{"award-number":["BRC-1215-20005"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.neubiorev.2023.105454","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:28:34Z","timestamp":1698953314000},"page":"105454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs"],"prefix":"10.1016","volume":"155","author":[{"given":"Rachel T.S.","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Favril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seena","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","article-title":"Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia","volume":"18","author":"Achtyes","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"7425","key":"10.1016\/j.neubiorev.2023.105454_bib2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: new approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227580","article-title":"Assessment of publication bias and outcome reporting bias in systematic reviews of health services and delivery research: a meta-epidemiological study","volume":"15","author":"Ayorinde","year":"2020","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/JCP.0000000000001169","article-title":"Acceptability of acute and maintenance pharmacotherapy of bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled clinical trials","volume":"40","author":"Bai","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2023.105454_bib5","unstructured":"BMJ Best Practice, n.d. Evidence based medicine (EBM) toolkit. Learn EBM. Search strategies. https:\/\/bestpractice.bmj.com\/info\/toolkit\/learn-ebm\/study-design-search-filters\/ (accessed 3 Dec 2020)."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105454_bib6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.neubiorev.2023.105454_bib7","article-title":"Umbrella review: association between antipsychotic drugs and metabolic syndrome hallmarks in children and adolescents","author":"Carnovale","year":"2023","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105454_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105454_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jad.2023.04.037","article-title":"Atypical antipsychotic-induced mania: a systematic review and meta-analysis","volume":"333","author":"C\u00f4rte-Real","year":"2023","journal-title":"J. Affect Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41380-022-01770-w","article-title":"The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: an umbrella review of the evidence from randomised controlled trials","volume":"28","author":"Croatto","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105454_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40263-019-00625-3","article-title":"Medication-Induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis","volume":"33","author":"Demyttenaere","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12888-020-02895-4","article-title":"Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013\u20132018","volume":"20","author":"Dennis","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-244X-7-40","article-title":"Atypical antipsychotics in bipolar disorder: systematic review of randomised trials","volume":"7","author":"Derry","year":"2007","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105454_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","article-title":"Ten simple rules for conducting umbrella reviews","volume":"21","author":"Fusar-Poli","year":"2018","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.neubiorev.2023.105454_bib17","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105454_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2215-0366(19)30286-X","article-title":"Long-term outcomes of childhood sexual abuse: an umbrella review","volume":"6","author":"Hailes","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105454_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011458","article-title":"Asenapine versus placebo for schizophrenia","author":"Hay","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105454_bib20","article-title":"The risk of antipsychotic drugs on breast cancer: a systematic review and meta-analysis","volume":"37","author":"Indrakusuma","year":"2022","journal-title":"Oman Med. J."},{"key":"10.1016\/j.neubiorev.2023.105454_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2023.105454_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105454_bib23","first-page":"1","article-title":"Efficacy and safety\/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis","volume":"53","author":"Kishimoto","year":"2022","journal-title":"Psychol. Med"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105454_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.0887-378X.2004.00327.x","article-title":"Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages","volume":"82","author":"Kravitz","year":"2004","journal-title":"Milbank Q"},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105454_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40263-016-0382-z","article-title":"Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trial","volume":"30","author":"Lao","year":"2016","journal-title":"CNS Drugs"},{"issue":"29","key":"10.1016\/j.neubiorev.2023.105454_bib26","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.neubiorev.2023.105454_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.11.008","article-title":"Effects of quetiapine on sleep: a systematic review and meta-analysis of clinical trials","volume":"67","author":"Lin","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2023.105454_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320982720","article-title":"Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies","volume":"11","author":"Liu","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2023.105454_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/NDT.S127453","article-title":"Efficacy and safety of olanzapine\/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials","volume":"13","author":"Luan","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neubiorev.2023.105454_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140579","article-title":"The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials","volume":"42","author":"Ma","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neubiorev.2023.105454_bib31","series-title":"AHRQ Comparative Effectiveness Reviews. Off-label use of atypical antipsychotics: an update. Rockville (MD)","author":"Maglione","year":"2011"},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105454_bib32","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-020-00688-1","article-title":"Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis","volume":"107","author":"Mortensen","year":"2020","journal-title":"Calcif. Tissue Int"},{"key":"10.1016\/j.neubiorev.2023.105454_bib34","unstructured":"National Library of Medicine, 2019. Search Strategy Used to Create the PubMed Systematic Reviews Filter. https:\/\/www.nlm.nih.gov\/bsd\/pubmed_subsets\/sysreviews_strategy.html (accessed 3 Dec 2020)."},{"key":"10.1016\/j.neubiorev.2023.105454_bib35","unstructured":"NHS Business Services Authority, 2020. Medicines used in mental health, England 2015\/16 to 2019\/20. https:\/\/nhsbsa-opendata.s3-eu-west-2.amazonaws.com\/mh-annual-narrative-final.html (accessed 7 Jun 2021)."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105454_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/pds.3804","article-title":"Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies","volume":"24","author":"Nos\u00e8","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib37","article-title":"Oral paliperidone for schizophrenia","author":"Nussbaum","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105454_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/schbul\/sbs099","article-title":"Paliperidone palmitate for schizophrenia","volume":"38","author":"Nussbaum","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105454_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105454_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0000000000000221","article-title":"Antipsychotic drug exposure and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"33","author":"Papola","year":"2018","journal-title":"Int Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105454_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"18","key":"10.1016\/j.neubiorev.2023.105454_bib42","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00213-015-4024-9","article-title":"The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach","volume":"232","author":"Polcwiartek","year":"2015","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2215-0366(22)00404-7","article-title":"Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000\u201319 primary care data","volume":"10","author":"Radoj\u010di\u0107","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105454_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.euroneuro.2022.12.010","article-title":"Second-generation antipsychotics and seizures - a systematic review and meta-analysis of serious adverse events in randomized controlled trials","volume":"68","author":"Reichelt","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105454_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/0269881118760661","article-title":"Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety","volume":"32","author":"Romeo","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2023.105454_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2019.12.118","article-title":"Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials","volume":"32","author":"Rotella","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105454_bib47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2215-0366(18)30177-9","article-title":"Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials","volume":"5","author":"Schneider-Thoma","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105454_bib48","article-title":"Fall-risk-increasing drugs: a systematic review and meta-Analysis: II. psychotropics","volume":"19","author":"Seppala","year":"2018","journal-title":"J. Am. Med Dir. Assoc."},{"key":"10.1016\/j.neubiorev.2023.105454_bib49","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105454_bib50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105454_bib51","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/nau.24695","article-title":"Urinary side effects of psychotropic drugs: a systematic review and metanalysis","volume":"40","author":"Trinchieri","year":"2021","journal-title":"Neurourol. Urodyn."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105454_bib52","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Method."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105454_bib54","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1017\/S003329171900401X","article-title":"The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis","volume":"51","author":"Wang","year":"2021","journal-title":"Psychol. Med"},{"key":"10.1016\/j.neubiorev.2023.105454_bib55","unstructured":"World Health Organization, 2019. World Health Organization model list of essential medicines, 2019. https:\/\/iris.who.int\/bitstream\/handle\/10665\/325771\/WHO-MVP-EMP-IAU-2019.06-eng.pdf?sequence=1 (accessed 9 Nov 2020)."},{"issue":"19","key":"10.1016\/j.neubiorev.2023.105454_bib56","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.24120","article-title":"Does antipsychotic drug use increase the risk of long term mortality? a systematic review and meta-analysis of observational studies","volume":"9","author":"Yang","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105454_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12888-019-2177-5","article-title":"Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis","volume":"19","author":"Zivkovic","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105454_bib58","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423004232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423004232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:37:07Z","timestamp":1758969427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763423004232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":58,"alternative-id":["S0149763423004232"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105454","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105454"}}